Addyi vs Vyleesi: Switching Between Flibanserin and Bremelanotide for HSDD

What HSDD Actually Means and Why Two Drugs Exist

Hypoactive sexual desire disorder affects an estimated 8% to 10% of U.S. women aged 20 to 49, according to prevalence data published in the Journal of Sexual Medicine. HSDD is defined as persistently low sexual desire that causes personal distress and is not better explained by another medical condition, medication, or relationship factor. For decades, no pharmacologic option existed. The FDA approved flibanserin (Addyi) in August 2015 and bremelanotide (Vyleesi) in June 2019, giving clinicians two mechanistically distinct tools.

The drugs differ in nearly every practical dimension: route of administration, onset, dosing cadence, side-effect profile, and alcohol restrictions. That divergence is exactly why switching between them is a realistic clinical pathway. A woman who cannot tolerate daily oral flibanserin or who drinks socially may find on-demand subcutaneous bremelanotide more workable. The reverse is also true: a patient who dislikes self-injection or experiences severe nausea with bremelanotide may prefer a nightly pill. No head-to-head randomized trial has compared the two agents directly, so the decision to switch rests on individual response, tolerability, and lifestyle fit.

How Addyi (Flibanserin) Works

Flibanserin is a mixed serotonin agonist/antagonist. It acts as a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist in the prefrontal cortex, modulating the balance between excitatory (dopamine, norepinephrine) and inhibitory (serotonin) neurotransmitter pathways involved in sexual desire. The drug was originally developed as an antidepressant, and its effects on desire were discovered during phase II depression trials.

Addyi is taken as a 100 mg tablet at bedtime every night. Bedtime dosing is required because the most common adverse effects, dizziness, somnolence, and hypotension, peak within one to two hours of ingestion. The FDA label carries a boxed warning about severe hypotension and syncope when flibanserin is combined with alcohol or moderate-to-strong CYP3A4 inhibitors. Women taking Addyi must avoid alcohol entirely.

Clinical benefit is not immediate. The BEGONIA trial (N=1,087) published in the Journal of Sexual Medicine showed that flibanserin 100 mg increased the number of satisfying sexual events by approximately 0.5 to 1.0 per month compared to placebo over 24 weeks, with statistically significant improvements on the Female Sexual Function Index (FSFI) desire domain. Pooled data from three key trials (DAISY, VIOLET, BEGONIA) showed a mean increase of 0.5 SSEs per month and a decrease of roughly 0.7 points on the Female Sexual Distress Scale-Revised (FSDS-R) Item 13 versus placebo.

Clinicians generally advise patients to continue Addyi for a minimum of 8 weeks before concluding it has failed, since the serotonergic rebalancing takes time.

How Vyleesi (Bremelanotide) Works

Bremelanotide is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It activates melanocortin-4 (MC4) receptors in the central nervous system, a pathway distinct from serotonin signaling, and is thought to enhance excitatory signals related to sexual arousal and desire. The mechanism does not overlap with flibanserin at all, which is the pharmacologic basis for attempting a switch.

Vyleesi is delivered as a 1.75 mg subcutaneous injection into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The RECONNECT phase III trials (two identically designed studies, combined N=1,247) published in Obstetrics & Gynecology demonstrated that bremelanotide significantly increased FSFI desire scores by 0.35 points over placebo and decreased FSDS-R desire-related distress by 0.7 points over 24 weeks. Response rates (defined as a clinically meaningful increase in desire or decrease in distress) were approximately 25% for bremelanotide versus 17% for placebo.

The on-demand model means a patient does not commit to a daily regimen. The FDA limits use to no more than 8 doses per calendar month, primarily because bremelanotide transiently raises blood pressure by 2 to 3 mmHg on average. It is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.

Nausea is the most frequent adverse event, occurring in about 40% of patients in the RECONNECT trials, although rates dropped to roughly 20% after the first few doses. There is no alcohol restriction.

Side-by-Side Comparison: Efficacy Data

No randomized trial has directly compared flibanserin to bremelanotide. Indirect comparison through their respective key trials requires caution because patient populations, baseline desire scores, and study designs differ. Still, clinicians and patients deserve a framework for contextualizing the data.

The BEGONIA trial enrolled premenopausal women meeting DSM-IV-TR criteria for HSDD and measured SSEs as the co-primary endpoint. The RECONNECT trials enrolled a similar population using DSM-5 criteria for female sexual interest/arousal disorder and used FSFI desire domain change and FSDS-R Item 13 change as co-primary endpoints. Both drugs showed statistically significant but modest effect sizes over placebo. An independent review published in the Annals of Internal Medicine described flibanserin's benefit as "small" and noted that the clinical significance of the observed differences remained debated.

In practice, a reasonable clinical heuristic is: if the absolute number of satisfying sexual events and subjective desire scores both improve within 8 to 12 weeks, the drug is working. If neither endpoint moves, switching is appropriate. If desire improves but distress persists (or vice versa), a longer trial or adjunctive behavioral therapy may be warranted before switching medications.

When Switching Makes Clinical Sense

Switching from Addyi to Vyleesi, or the reverse, is appropriate in three scenarios.

Inadequate efficacy. Flibanserin requires 8 weeks of daily dosing to judge response. If a patient reports no meaningful change in desire or SSEs after this period, discontinuation and a trial of bremelanotide is a logical next step. Because the mechanisms do not overlap, failure on one agent does not predict failure on the other. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction supports sequential pharmacologic trials when nonpharmacologic interventions alone are insufficient.

Intolerable side effects. Flibanserin's sedation, dizziness, and absolute alcohol restriction are the most common reasons women discontinue it. Real-world data from the FLIBANSERIN REMS program showed that a substantial number of prescriptions were never refilled, suggesting tolerability barriers. Bremelanotide's injection-site reactions and nausea may similarly drive discontinuation, making Addyi the alternative.

Lifestyle incompatibility. A woman who travels frequently and cannot maintain a strict nightly schedule may prefer on-demand bremelanotide. A woman who is uncomfortable with self-injection may prefer oral flibanserin. Neither preference is clinically wrong.

How to Switch Safely

There is no published washout protocol specific to the flibanserin-to-bremelanotide transition (or the reverse). Pharmacokinetic data guide the practical approach.

Flibanserin has a half-life of approximately 11 hours. After stopping Addyi, the drug is functionally eliminated within 2 to 3 days. Because flibanserin's main risks (hypotension, syncope) are mediated through serotonergic and adrenergic mechanisms that do not interact with melanocortin receptors, there is no pharmacologic rationale for delaying bremelanotide initiation beyond the standard few-day clearance window.

Bremelanotide has a half-life of roughly 2.7 hours. Its effects dissipate within 12 to 16 hours. Switching from Vyleesi to Addyi can therefore begin the next day, though the patient should be counseled that Addyi will not produce noticeable effects for several weeks.

A clinical reassessment at the time of switching should include a blood pressure check (relevant if starting bremelanotide), a medication reconciliation for CYP3A4 interactions (relevant if starting flibanserin), and a conversation about realistic timelines for benefit.

Alcohol, Drug Interactions, and Contraindications

This is where the two agents diverge most sharply in day-to-day impact. Addyi's REMS program exists primarily because of the alcohol-flibanserin interaction: combining even moderate alcohol with flibanserin can cause dangerous hypotension and syncope. The interaction is pharmacodynamic, not pharmacokinetic, and cannot be mitigated by timing. Women who drink socially, even occasionally, face a real practical barrier with Addyi.

Bremelanotide carries no alcohol restriction. Its primary contraindication is uncontrolled hypertension, because the drug raises systolic blood pressure by an average of 3 mmHg and diastolic by 1 to 2 mmHg within 2 to 4 hours of injection, per the FDA prescribing information. This increase is transient but may be clinically significant for women on antihypertensive regimens or with cardiovascular risk factors.

Flibanserin is metabolized by CYP3A4, meaning drugs like fluconazole, ketoconazole, and certain HIV protease inhibitors are contraindicated. Even moderate CYP3A4 inhibitors require dose adjustment or avoidance. Bremelanotide is not hepatically metabolized to a clinically meaningful degree and has no known CYP-mediated drug interactions, though it may slow absorption of co-administered oral medications due to transient gastrointestinal slowing.

Insurance, Cost, and Access Barriers

Both Addyi and Vyleesi carry high list prices. Flibanserin, available since 2015 and now offered by several generic manufacturers since Sprout Pharmaceuticals' exclusivity ended, has seen prices drop. Cash-pay prices for generic flibanserin range from $30 to $80 per month at major pharmacies. Brand-name Addyi may still list above $400 per month.

Bremelanotide remains under brand exclusivity. The wholesale acquisition cost is approximately $900 for a carton of 4 autoinjectors (4 doses), translating to roughly $1,800 per month at the 8-dose maximum. Insurance coverage is inconsistent. Many plans require prior authorization, documented failure of behavioral therapy, and sometimes prior failure of flibanserin before approving bremelanotide.

This cost asymmetry influences switching decisions. A patient who fails generic flibanserin faces a substantial cost escalation if bremelanotide is not covered. The AAFP position statement on prior authorization has noted that requirements in sexual health disproportionately delay care for women.

Long-Term Safety Considerations

Flibanserin has the longer post-market track record, with prescribing data now spanning over a decade. The FDA's post-marketing safety review confirmed that the hypotension-syncope risk is real but manageable with label adherence. No new safety signals have emerged regarding hepatotoxicity or serotonin syndrome at standard doses.

Bremelanotide's label notes that focal areas of skin hyperpigmentation occurred in about 1% of clinical trial participants, related to melanocortin-receptor activation in melanocytes. These patches were cosmetic, not pre-malignant, and typically resolved after discontinuation. The 8-dose monthly cap exists partly to limit cumulative melanocortin exposure, though long-term carcinogenicity data in humans remain limited to the trial follow-up period of 12 months.

Neither drug has been studied in postmenopausal women with HSDD, and neither is FDA-approved for that population. Off-label use does occur, but clinicians should acknowledge the evidence gap.

What the Guidelines Say

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care algorithm for HSDD in 2018 that places both flibanserin and bremelanotide as pharmacologic options after biopsychosocial assessment, sex therapy or counseling, and identification of modifiable contributors (medications, hormonal status, relationship factors).

Dr. Sheryl Kingsberg, a lead investigator on both the BEGONIA and RECONNECT programs, stated in a 2019 commentary: "Having two mechanistically distinct options allows clinicians to personalize treatment in a way that was simply not possible before 2019. If one path does not work, the other may, and there is no pharmacologic reason not to try."

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction (No. 213, 2019) acknowledges both agents and recommends shared decision-making that weighs efficacy, side effects, and patient preferences.

Putting It Together: A Decision Framework for Clinicians

For a premenopausal woman with diagnosed HSDD who has already addressed modifiable factors, the practical algorithm is straightforward.

Start with the agent whose profile best matches the patient's life. If she takes no CYP3A4 interacting medications, does not drink alcohol, and prefers a daily routine, flibanserin is a reasonable first choice. Generic pricing makes it more accessible. If she drinks socially, has an irregular schedule, or prefers on-demand dosing, bremelanotide may be the better starting point.

Reassess at 8 weeks for flibanserin or after 4 to 6 uses for bremelanotide. If response is absent and side effects are tolerable, continue for another 4 weeks. If side effects are intolerable or no response is seen at 12 weeks (flibanserin) or after 8 uses (bremelanotide), switch to the other agent. Document the reason for switching. If both agents fail, refer for multidisciplinary evaluation including endocrine workup and specialized sex therapy.

Prescribers should check blood pressure before starting bremelanotide and review the patient's full medication list for CYP3A4 interactions before starting flibanserin. The REMS certification for flibanserin requires prescriber and pharmacy enrollment.